423
Views
29
CrossRef citations to date
0
Altmetric
Original Research

Comparing the Performance of Charlson and Elixhauser Comorbidity Indices to Predict In-Hospital Mortality Among a Chinese Population

ORCID Icon, , , , , , ORCID Icon & show all
Pages 307-316 | Published online: 18 Mar 2020
 

Abstract

Objective

Earlier comorbidity measures have been developed or validated using the North American population. This study aims to compare five Charlson or Elixhauser comorbidity indices to predict in-hospital mortality using a large electronic medical record database from Shanxi, China.

Methods

Using the primary diagnosis code and surgery procedure codes, we identified four hospitalized patient cohorts, hospitalized between 2013 and 2017, in Shanxi, China, as follows: congestive heart failure (CHF, n=41,577), chronic renal failure (CRF, n=40,419), diabetes (n=171,355), and percutaneous coronary intervention (PCI, n=39,097). We used logistic regression models and c-statistics to evaluate the in-hospital mortality predictive performance of two multiple comorbidity indicator variables developed by Charlson in 1987 and Elixhauser in 1998 and three single numeric scores by Quan in 2011, van Walraven in 2009, and Moore 2017.

Results

Elixhauser comorbidity indicator variables had consistently higher c-statistics (0.824, 0.843, 0.904, 0.853) than all other four comorbidity measures, across all four disease cohorts. Moore’s comorbidity score outperformed the other two score systems in CHF, CRF, and diabetes cohorts (c-statistics: 0.776, 0.832, 0.869), while van Walraven’s score outperformed all others among PCI patients (c-statistics: 0.827).

Conclusion

Elixhauser comorbidity indicator variables are recommended, when applied to large Chinese electronic medical record databases, while Moore’s score system is appropriate for relatively small databases.

Acknowledgments

The authors thank the Health and Family Planning Commission in Shanxi, China for providing us with the data used in this study.

Disclosure

The authors report no conflicts of interest in this work.